Table 1.
Baseline parameters of Fluocinolone Acetonide implant treated eyes
| Parameter | Value |
|---|---|
| Visual Acuity (ETDRS letters) | Range (2–85), Mean (50.7) |
| Central Retinal Thickness (Micrometers) | Range (373–1052) .Mean (631) |
| Duration of DMO(Months) | Range (9-47). Mean (26.2) |
| Foveal eversion | 21 |
| Pseudophakia | 22 |
| Eyes with one co-existing pathology | ERM(n = 11) |
| VMT(n = 2) | |
| Glaucoma/Ocular hypertension (n = 4) | |
| NVD n = 1 | |
| NVE n = 1 | |
| Eyes with >1 co-existing pathologies | 3 |
| Eyes on IOP lowering drugs | 4 |
| Eyes with prior macular laser only | 15 |
| Eyes with prior vitrectomy for DMO/ERM | 1 |
| Eyes with prior intravitreal therapy | Ranibizumab only– n = 11 |
| Bevacizumab only n = 2 | |
| Rani and Beva n = 3 | |
| Triamcinolone n = 6 | |
| Eyes with prior PRP | 9 |